Last reviewed · How we verify
High-Dose Influenza Vaccine
High-dose influenza vaccine stimulates a stronger immune response by delivering a higher antigen load to enhance antibody production and cellular immunity against influenza viruses.
High-dose influenza vaccine stimulates a stronger immune response by delivering a higher antigen load to enhance antibody production and cellular immunity against influenza viruses. Used for Prevention of influenza in adults aged 65 years and older, Prevention of influenza in immunocompromised adults.
At a glance
| Generic name | High-Dose Influenza Vaccine |
|---|---|
| Also known as | Fluzone High-Dose |
| Sponsor | Saad Jamshed MD |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains four times the standard antigen dose (60 mcg per strain vs. 15 mcg in standard-dose vaccine), which triggers more robust B-cell and T-cell responses. This enhanced immunogenicity is particularly beneficial in older adults and immunocompromised populations who may have diminished responses to standard-dose vaccines.
Approved indications
- Prevention of influenza in adults aged 65 years and older
- Prevention of influenza in immunocompromised adults
Common side effects
- Injection site soreness
- Myalgia
- Fatigue
- Headache
- Low-grade fever
Key clinical trials
- Influenza A (H7N9) Vaccine Delivered Intradermally by High-density Microarray Patch (HD-MAP) (PHASE1)
- This is an Early-stage Clinical Trial to Determine a Safe and Effective Dose for Tivoxavir Marboxil in Patients With Mild to Moderate Influenza (PHASE2)
- A Trial to Evaluate the Effect of CD388 on the Immunogenicity of Fluzone® HD Vaccine (PHASE1)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- First-in-Human Study of VNT-101: Safety, Tolerability, and Pharmacokinetics (PHASE1)
- Reduced Intensity Haploidentical BMT for High Risk Solid Tumors (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-Dose Influenza Vaccine CI brief — competitive landscape report
- High-Dose Influenza Vaccine updates RSS · CI watch RSS
- Saad Jamshed MD portfolio CI